NXGL Nexgel (NXGL) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001468929
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
10
13F, latest reported quarter
What the filings say about NXGL
Insiders, 180 days
-$20.8K net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.5K
1 notice
Nexgel insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, NEXGEL, INC. insiders sold a net $20.8K of stock across 92 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 25 earlier Form 4 trades (code P or S) here by this insider (1 buy, 24 sales), the last on Jun 18, 2026.
- The trade is 1.5% of the 322,692 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Levy Adam R. sold about $3.0K of NXGL on Jun 23, 2026; 10 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (1 buy, 23 sales), the last on Jun 11, 2026.
- The trade is 1.8% of the 327,692 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Levy Adam R. sold about $3.5K of NXGL on Jun 18, 2026; 10 funds added in the latest 13F quarter.Context
- 23 earlier Form 4 trades (code P or S) here by this insider (1 buy, 22 sales), the last on Jun 8, 2026.
- The trade is 0.9% of the 333,692 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Levy Adam R. sold about $1.8K of NXGL on Jun 11, 2026; 10 funds added in the latest 13F quarter.Context
- 22 earlier Form 4 trades (code P or S) here by this insider (1 buy, 21 sales), the last on Jun 4, 2026.
- The trade is 0.9% of the 336,692 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Levy Adam R. sold about $1.7K of NXGL on Jun 8, 2026; 10 funds added in the latest 13F quarter.Context
- 21 earlier Form 4 trades (code P or S) here by this insider (1 buy, 20 sales), the last on Jun 1, 2026.
- The trade is 0.9% of the 339,692 shares held after it.
- No other insider sold within 30 days.
- 10 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Levy Adam R. sold about $1.8K of NXGL on Jun 4, 2026; 10 funds added in the latest 13F quarter.92 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$20.8K over 180 days
more than 60% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
10 funds bought in last quarter
below 85% of Medical Devices
Revenue
+31.5% year over year
more than 80% of Medical Devices
Margin
-26.3% net margin
below 57% of Medical Devices
Buybacks
no share repurchases reported
Short interest
84.0% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 52% of Medical Devices
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Sep 30Affilaite Levy Adam R. filed to sell $3.5K by Sep 29 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch NXGL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+51.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns NXGL: institutional holders (13F)
13F holdings, latest reported quarter
85,140 sh
$42.7K
71,863 sh
$36.0K
54,980 sh
$27.5K
48,920 sh
$24.5K
550,000 sh
$21.2K
Congress trades in NXGL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
NXGL planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Levy Adam R.
Filed 2026-09-30
$3.5K
NXGL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$56.0K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$24.5K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$8.2K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$5.2K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$328 position · as of 2026-05-31
0.0%
U.S. MICRO CAP PORTFOLIO
$82 position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $20.8K sold by insiders over 180 days, 10 funds added last quarter, $3.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
NXGL financials
Revenue growth
+31.5%
XBRL, annual
Net margin
-26.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$12.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM NXGL
| FY Dec 2025 | $11.4M |
| FY Dec 2024 | $8.7M |
| FY Dec 2023 | $4.1M |
| FY Dec 2022 | $2.0M |
| FY Dec 2021 | $1.6M |
| Jun 2026 | $3.7M |
| Mar 2026 | $2.6M |
| Dec 2025 | $2.8M |
| Sep 2025 | $2.9M |
| Jun 2025 | $2.9M |
| Mar 2025 | $2.8M |
| Dec 2024 | $3.0M |
| Sep 2024 | $2.9M |
At each fiscal year end
Single quarter
Net margin, TTM
-51.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM NXGL
| FY Dec 2025 | -26.3% |
| FY Dec 2024 | -37.8% |
| FY Dec 2023 | -77.2% |
| FY Dec 2022 | -231.6% |
| FY Dec 2021 | -277.7% |
| Jun 2026 | -98.6% |
| Mar 2026 | -35.0% |
| Dec 2025 | -34.7% |
| Sep 2025 | -22.3% |
| Jun 2025 | -23.1% |
| Mar 2025 | -25.4% |
| Dec 2024 | -28.0% |
| Sep 2024 | -23.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$3.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM NXGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$4.3M |
| FY Dec 2023 | -$3.9M |
| FY Dec 2022 | -$3.1M |
| FY Dec 2021 | -$3.0M |
| Jun 2026 | -$2.3M |
| Mar 2026 | -$513.0K |
| Dec 2025 | $241.0K |
| Sep 2025 | -$793.0K |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$928.0K |
| Sep 2024 | -$1.2M |
At each fiscal year end
Single quarter
Debt to equity
0.69x
long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end); equity 2026-06-30
Debt to equity NXGL
| FY Dec 2025 | 0.21x |
| FY Dec 2024 | 0.18x |
| FY Dec 2023 | 0.18x |
| FY Dec 2022 | 0.04x |
| FY Dec 2021 | 10.54x |
| Jun 2026 | 0.69x |
| Mar 2026 | 0.23x |
| Dec 2025 | 0.21x |
| Sep 2025 | 0.18x |
| Jun 2025 | 0.21x |
| Mar 2025 | 0.19x |
| Dec 2024 | 0.18x |
| Sep 2024 | 0.22x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.94x
TTM operating cash flow over long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end)
Cash flow to debt NXGL
| FY Dec 2025 | -1.41x |
| FY Dec 2024 | -3.75x |
| FY Dec 2023 | -3.86x |
| FY Dec 2022 | -10.57x |
| FY Dec 2021 | -0.02x |
| Jun 2026 | -0.94x |
| Mar 2026 | -1.56x |
| Dec 2025 | -1.41x |
| Sep 2025 | -2.56x |
| Jun 2025 | -2.93x |
| Mar 2025 | -3.15x |
| Dec 2024 | -3.75x |
| Sep 2024 | -3.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-128.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity NXGL
| FY Dec 2025 | -58.7% |
| FY Dec 2024 | -62.8% |
| FY Dec 2023 | -51.2% |
| FY Dec 2022 | -48.1% |
| FY Dec 2021 | -70.9% |
| Jun 2026 | -128.6% |
| Mar 2026 | -69.9% |
| Dec 2025 | -58.7% |
| Sep 2025 | -58.3% |
| Jun 2025 | -66.1% |
| Mar 2025 | -62.8% |
| Dec 2024 | -62.8% |
| Sep 2024 | -68.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-34.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets NXGL
| FY Dec 2025 | -28.0% |
| FY Dec 2024 | -31.3% |
| FY Dec 2023 | -31.1% |
| FY Dec 2022 | -34.7% |
| FY Dec 2021 | -44.8% |
| Jun 2026 | -34.2% |
| Mar 2026 | -29.2% |
| Dec 2025 | -28.0% |
| Sep 2025 | -26.0% |
| Jun 2025 | -30.0% |
| Mar 2025 | -30.2% |
| Dec 2024 | -31.3% |
| Sep 2024 | -34.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital NXGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-55.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed NXGL
| FY Dec 2025 | -41.9% |
| FY Dec 2024 | -44.7% |
| FY Dec 2023 | -41.1% |
| FY Dec 2022 | -28.4% |
| FY Dec 2021 | -34.2% |
| Jun 2026 | -55.9% |
| Mar 2026 | -43.6% |
| Dec 2025 | -41.9% |
| Sep 2025 | -37.6% |
| Jun 2025 | -42.1% |
| Mar 2025 | -43.7% |
| Dec 2024 | -44.7% |
| Sep 2024 | -49.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing NXGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$41.1M
market value at close 2026-10-26 on 2026-08-14 shares, plus long-term 2026-06-30 plus current 2024-09-30 (21 months older than the period end), minus cash 2025-09-30
Enterprise value NXGL
| FY Dec 2025 | $13.1M |
| FY Dec 2024 | $29.5M |
| FY Dec 2023 | $10.3M |
| FY Dec 2022 | $5.8M |
| FY Dec 2021 | $386.2M |
| Jun 2026 | $7.0M |
| Mar 2026 | $5.3M |
| Dec 2025 | $13.1M |
| Sep 2025 | $19.7M |
| Jun 2025 | $18.9M |
| Mar 2025 | $22.0M |
| Dec 2024 | $29.5M |
| Sep 2024 | $16.3M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-8.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield NXGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | -14.2% |
| FY Dec 2023 | -32.3% |
| FY Dec 2022 | -44.3% |
| FY Dec 2021 | -1.1% |
| Jun 2026 | -73.0% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | -16.8% |
| Mar 2025 | -15.9% |
| Dec 2024 | -14.2% |
| Sep 2024 | -24.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing NXGL
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $11.4M | $8.7M | $4.1M | $2.0M |
| Gross profit | $4.5M | $2.7M | $374.0K | $256.0K |
| Operating income | -$3.4M | -$3.6M | -$3.5M | -$3.3M |
| Net income | -$3.0M | -$3.3M | -$3.2M | -$4.7M |
| EPS (diluted) | -0.38 | -0.50 | -0.56 | -0.85 |
| Operating cash flow | -$1.3M | -$3.9M | -$3.2M | -$3.0M |
| Cash | n/a | $1.8M | $2.7M | n/a |
| Long-term debt | $588.0K | $685.0K | $593.0K | $283.0K |
SEC XBRL, fiscal years, as known on 2026-10-28
NXGL Stock Sonar score 6/7 axes
Find similar shapesCompareNXGL ranks highest on growth (80th percentile) and risk and compliance (46th), and lowest on institutional and government (15th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
NXGL filings, in plain words
Are Nexgel insiders buying or selling NXGL?
In the 180 days to 2026-10-28, Nexgel insiders were net sellers, a net $20.8K across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of NXGL?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $3.5K of stock; the latest, by Levy Adam R., was filed 2026-09-30.
Read the full summary
In the 180 days to 2026-10-28, Nexgel insiders were net sellers of NXGL, a net $20.8K across purchases and sales reported on Form 4 by 1 seller. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $3.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
